High affinity proteasome inhibitor
Bortezomib is a high affinity proteasome inhibitor (Ki = 0.6 nM). Inhibits growth of multiple myeloma (MM) cell lines (IC50 values in <50 nM range); induces apoptosis in MM cell lines and MM patient derived cells, including p53 mutant cell lines. Decreases adherence of MM cells lines to bone marrow stromal cells (BMSCs). Acts synergistically with dexamethasone (Cat. No. 1126). Also cytotoxic in MCF-7 breast cancer cell line (IC50 = 50 nM).
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-124821 |
| Réf. fabricant | 18747636 |
| Nom chimique ou matériau | B-[(1 R)-3-Methyl-1-[[(2 S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid |
| CAS | 179324-69-7 |
| Quantité | 5 mg |
| Cible | Proteasome Inhibitors |
| Formule moléculaire | C<sub>19</sub>H<sub>25</sub>BN<sub>4</sub>O<sub>4</sub> |
| Pureté | 0.98 |
